NCT00501943View on ClinicalTrials.gov

Neuroprotection With Riluzole Patients With Early Multiple Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Multiple Sclerosis
Interventions
DRUG

Avonex (Interferon beta 1a)

DRUG

Riluzole

DRUG

Placebo

Trial Locations (1)

94158

UCSF MS Center , 675 Nelson Rising Lane, Suite 221, San Francisco

All Listed Sponsors
collaborator

National Multiple Sclerosis Society

OTHER

collaborator

Oregon Health and Science University

OTHER

lead

University of California, San Francisco

OTHER

NCT00501943 - Neuroprotection With Riluzole Patients With Early Multiple Sclerosis | Biotech Hunter | Biotech Hunter